Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1)

Diabetes Technology and Therapeutics

Volumn 19, Issue 1, 2017, Pages 49-60

  Famulla, Susanne ^a   Pieber, Thomas R ^b   Eilbracht, Jens ^c   Neubacher, Dietmar ^c   Soleymanlou, Nima ^d   Woerle, Hans J ^c   Broedl, Uli C ^c   Kaspers, Stefan ^c  

^a Profil Outpatient Trials GmbH   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

Continuous glucose monitoring; HbA1c; Hyperglycemia; Hypoglycemia; Postprandial blood glucose; Type 1 diabetes

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE;

ADD ON THERAPY; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; BOLUS INJECTION; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PHARMACEUTICAL CARE; PHASE 2 CLINICAL TRIAL; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ANALYSIS; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 1; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 85010021743     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2016.0261     Document Type: Article

References (22)

1. Pieber TR, Famulla S, Eilbracht J, et al.: Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 2015;17:928-935.
2. Kilpatrick ES, Rigby AS, Goode K, et al.: Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 2007;50:2553-2561.
3. Kilpatrick ES, Rigby AS, Atkin SL: A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 2008;31:2198-2202.
4. Bragd J, Adamson U, Backlund LB, et al.: Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade? Diabetes Metab 2008;34:612-616.
5. Sartore G, Chilelli NC, Burlina S, et al.: Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes. Acta Diabetol 2013;50:437-442.
6. Roden M, Weng J, Eilbracht J, et al.: Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, placebocontrolled, phase 3 trial. Lancet Diabetes Endocrinol 2013;1: 208-219.
7. Kovacs CS, Seshiah V, Swallow R, et al.: Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebocontrolled trial. Diabetes Obes Metab 2014;16:147-158.
8. Häring HU, Merker L, Seewaldt-Becker E, et al.: Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebocontrolled trial. Diabetes Care 2014;37:1650-1659.
9. Häring HU, Merker L, Seewaldt-Becker E, et al.: Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, doubleblind, placebo-controlled trial. Diabetes Care 2013;36: 3396-3404.
10. Henry RR, Thakkar P, Tong C, et al.: Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 2015;38:2258-2265.
11. Tamez HE, Tamez AL, Garza LA, et al.: Dapagliflozin as an adjunct therapy to insulin in the treatment of patientswith type 1 diabetes mellitus. J Diabetes Metab Disord 2015;14:78.
12. Rosenstock J, Aggarwal N, Polidori D, et al.: Dose-ranging effects of canagliflozin, a sodium-glucose cotransporteraor2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232-1238.
13. Rosenstock J, Vico M, Wei L, et al.: Effects of dapagliflozin, an SGLT2 inhibitor, on HbA (1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012;35:1473-1478.
14. Wilding JP, Ferrannini E, Fonseca VA, et al.: Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab 2013;15:403-409.
15. Nauck M, Del Prato S, Meier J, et al.: Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-2022.
16. Perkins BA, Cherney DZ, Soleymanlou N, et al.: Diurnal glycemic patterns during an 8-week open-label proof-ofconcept trial of empagliflozin in type 1 diabetes. PloS One 2015;10:e0141085.
17. Sands AT, Zambrowicz BP, Rosenstock J, et al.: Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 2015;38: 1181-1188.
18. Henry RR, Rosenstock J, Edelman S, et al.: Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015;38:412-419.
19. Weinstock RS, Xing D, Maahs DM, et al.: Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab 2013;98:3411-3419.
20. Peters AL, Buschur EO, Buse JB, et al.: Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015;38:1687-1693.
21. Zijlstra E, Heise T, Nosek L, et al.: Continuous glucose monitoring: quality of hypoglycaemia detection. Diabetes Obes Metab 2013;15:130-135.
22. Bergenstal RM, Ahmann AJ, Bailey T, et al.: Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile. J Diabetes Sci Technol 2013;7:562-578.